Understanding and Managing Corticosteroid-Induced Osteoporosis

Area of Science:

• Endocrinology
• Bone Biology
• Pharmacology

Background:

• Glucocorticoids are potent immunosuppressants with widespread clinical use.
• Chronic glucocorticoid therapy leads to secondary osteoporosis in 30-50% of patients.
• Bone strength rapidly declines within 3-6 months due to increased osteoclast activity.

Purpose of the Study:

• To review the mechanisms of glucocorticoid-induced bone loss.
• To highlight the underdiagnosis and undertreatment of glucocorticoid-induced osteoporosis.
• To discuss current and future management strategies for preventing fractures.

Main Methods:

• Review of existing literature on glucocorticoid effects on bone.
• Analysis of current clinical practices in managing glucocorticoid-induced osteoporosis.
• Evaluation of pharmacological and non-pharmacological interventions.

Main Results:

• Glucocorticoids induce bone loss via increased resorption and decreased formation, affecting bone quality beyond density.
• Bone mineral density measurements may not fully reflect glucocorticoid-induced bone loss.
• Trabecular bone score and advanced imaging offer insights into bone quality but are underutilized.

Conclusions:

• Glucocorticoid-induced osteoporosis is a preventable condition with suboptimal current management (only 15% receive optimal care).
• Lowest effective dose and shortest duration of glucocorticoids are crucial.
• Lifestyle counseling and pharmacological interventions (bisphosphonates, osteoanabolic agents) are recommended for at-risk patients.